{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T01:04:41Z","timestamp":1780707881337,"version":"3.54.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.euros.2025.12.004","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T22:01:59Z","timestamp":1766181719000},"page":"133-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Long-term Real-world Survival Outcomes with Dual Immune Checkpoint Blockade in Synchronous Metastatic Renal Cell Carcinoma: Implications for the Design of Prospective Cytoreductive Nephrectomy Trials"],"prefix":"10.1016","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4221-4434","authenticated-orcid":false,"given":"Leo","family":"Bickley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth E.","family":"Fransen van de Putte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luna","family":"van den Brink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Marandino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes C.","family":"van der Mijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Wilgenhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes V.","family":"van Thienen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.A.G.","family":"Haanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterini","family":"Boleti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Powles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia J.","family":"Zondervan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels M.","family":"Graafland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zayd","family":"Tippu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samra","family":"Turajlic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Bex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2025.12.004_b0005","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euros.2025.12.004_b0010","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMoa003013","article-title":"Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer","volume":"345","author":"Flanigan","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2025.12.004_b0015","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0140-6736(01)06103-7","article-title":"European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial","volume":"358","author":"Mickisch","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.euros.2025.12.004_b0020","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1803675","article-title":"Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma","volume":"379","author":"M\u00e9jean","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2025.12.004_b0025","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamaoncol.2018.5543","article-title":"Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial","volume":"5","author":"Bex","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euros.2025.12.004_b0030","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.eururo.2022.03.006","article-title":"European Association of Urology guidelines on renal cell carcinoma: the 2022 update","volume":"82","author":"Ljungberg","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.12.004_b0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3233\/KCA-210010","article-title":"\u2018PROBE\u2019ing the role of cytoreductive nephrectomy in advanced renal cancer","volume":"6","author":"Bell","year":"2022","journal-title":"Kidney Cancer J"},{"key":"10.1016\/j.euros.2025.12.004_b0040","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/s12885-024-11987-3","article-title":"Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial","volume":"24","author":"Iisager","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euros.2025.12.004_b0045","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3233\/KCA-220004","article-title":"What we have learnt from CARMENA and SURTIME and what should be done differently in future trials on cytoreductive nephrectomy","volume":"6","author":"Zondervan","year":"2022","journal-title":"Kidney Cancer"},{"key":"10.1016\/j.euros.2025.12.004_b0050","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.clgc.2020.04.002","article-title":"Elective cytoreductive nephrectomy after checkpoint inhibitor immunotherapy in patients with initially unresectable metastatic clear cell renal cell carcinoma","volume":"18","author":"Reimers","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euros.2025.12.004_b0055","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.21873\/anticanres.15751","article-title":"Impact of cytoreductive nephrectomy following nivolumab plus ipilimumab therapy for patients with advanced renal cell carcinoma","volume":"42","author":"Shirotake","year":"2022","journal-title":"Anticancer Res"},{"key":"10.1016\/j.euros.2025.12.004_b0060","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.urolonc.2019.08.012","article-title":"Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma","volume":"37","author":"Singla","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euros.2025.12.004_b0065","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.euo.2022.07.002","article-title":"Oncological outcomes of delayed nephrectomy after optimal response to immune checkpoint inhibitors for metastatic renal cell carcinoma","volume":"5","author":"Pignot","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euros.2025.12.004_b0070","doi-asserted-by":"crossref","first-page":"604.e9","DOI":"10.1016\/j.urolonc.2020.02.029","article-title":"Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: an analysis of the national cancer database","volume":"38","author":"Singla","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euros.2025.12.004_b0075","doi-asserted-by":"crossref","first-page":"51.e25","DOI":"10.1016\/j.urolonc.2022.08.013","article-title":"A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy","volume":"41","author":"Gross","year":"2023","journal-title":"Urol Oncol"},{"issue":"Suppl 4","key":"10.1016\/j.euros.2025.12.004_b0080","article-title":"Outcomes of deferred cytoreductive nephrectomy following primary immunotherapy in advanced renal cell carcinoma: a multicenter analysis","volume":"209","author":"Hakimi","year":"2023","journal-title":"J Urol"},{"issue":"Suppl 1","key":"10.1016\/j.euros.2025.12.004_b0085","doi-asserted-by":"crossref","first-page":"S1864","DOI":"10.1016\/S0302-2838(24)01412-X","article-title":"Delayed nephrectomy after immunotherapy for metastatic renal cell carcinoma: oncological outcomes and predictive factors of surgical difficulties","volume":"85","author":"Pignot","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.12.004_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102177","article-title":"Pathological response and outcomes in patients with metastatic renal cell carcinoma (mRCC) receiving immunotherapy-based therapies and undergoing deferred cytoreductive nephrectomy (CN)","volume":"22","author":"Gunenc","year":"2024","journal-title":"Clin Genitourin Cancer"},{"issue":"5 Suppl","key":"10.1016\/j.euros.2025.12.004_b0095","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1200\/JCO.2025.43.5_suppl.468","article-title":"Extensive necrosis as a prognostic indicator in metastatic RCC patients undergoing deferred cytoreductive nephrectomy after immunologic checkpoint inhibitor treatment","volume":"43","author":"do Amaral","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2025.12.004_b0100","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.euros.2021.11.003","article-title":"Primary renal tumour response in patients treated with nivolumab and ipilimumab for metastatic renal cell carcinoma: real-world data assessment","volume":"35","author":"Meerveld-Eggink","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euros.2025.12.004_b0105","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.euros.2023.07.002","article-title":"Indications and outcomes for deferred cytoreductive nephrectomy following immune checkpoint inhibitor combination therapy: can systemic therapy be withdrawn in patients with no evidence of disease?","volume":"55","author":"Fransen van de Putte","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euros.2025.12.004_b0110","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euros.2025.12.004_b0115","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.566297","article-title":"Dissociated response in metastatic cancer: an atypical pattern brought into the spotlight with immunotherapy","volume":"10","author":"Humbert","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.euros.2025.12.004_b0120","doi-asserted-by":"crossref","first-page":"498.e1","DOI":"10.1016\/j.clgc.2022.06.006","article-title":"Primary tumor shrinkage and the effect on metastatic disease and outcomes in patients with advanced kidney cancer with intermediate or poor prognosis treated with nivolumab plus ipilimumab or cabozantinib","volume":"20","author":"Iacovelli","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euros.2025.12.004_b0125","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1198\/000313005X70371","article-title":"Illustrating the impact of a time-varying covariate with an extended Kaplan-Meier estimator","volume":"59","author":"Snapinn","year":"2005","journal-title":"Am Stat"},{"key":"10.1016\/j.euros.2025.12.004_b0130","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.euo.2023.10.002","article-title":"Characterization of patients with metastatic renal cell carcinoma undergoing deferred, upfront, or no cytoreductive nephrectomy in the era of combination immunotherapy: results from the International Metastatic Renal Cell Carcinoma Database Consortium","volume":"7","author":"Takemura","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euros.2025.12.004_b0135","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.3390\/curroncol31080351","article-title":"Impact of timing of immunotherapy and cytoreductive nephrectomy in metastatic renal cell carcinoma: real-world data on survival outcomes from the CKCis database","volume":"31","author":"Park","year":"2024","journal-title":"Curr Oncol"},{"key":"10.1016\/j.euros.2025.12.004_b0140","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.eururo.2021.10.001","article-title":"First-line nivolumab plus ipilimumab versus sunitinib in patients without nephrectomy and with an evaluable primary renal tumor in the CheckMate 214 trial","volume":"81","author":"Albiges","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.12.004_b0145","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2025.12.004_b0150","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1007\/s10147-022-02215-8","article-title":"Real-world efficacy and safety of nivolumab plus ipilimumab in untreated metastatic renal cell carcinoma, and the impact of previous nephrectomy on clinical outcome: Japanese multi-institutional retrospective study","volume":"27","author":"Kato","year":"2022","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.euros.2025.12.004_b0155","first-page":"1345","article-title":"Real-world effectiveness of nivolumab plus ipilimumab and second-line therapy in Japanese untreated patients with metastatic renal cell carcinoma: 2-year analysis from a multicenter retrospective clinical study (J-Cardinal study)","volume":"52","author":"Kojima","year":"2022","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.euros.2025.12.004_b0160","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s00345-024-05133-8","article-title":"Systemic therapies and primary tumour downsizing in renal cell carcinoma: a real-world comparison of anti-angiogenic and immune checkpoint inhibition regimens","volume":"42","author":"Bickley","year":"2024","journal-title":"World J Urol"},{"key":"10.1016\/j.euros.2025.12.004_b0165","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.3390\/cancers14122867","article-title":"Metastatic clear-cell renal cell carcinoma in the era of immune checkpoint inhibitors: therapies and ongoing trials","volume":"14","author":"Zhuang","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.euros.2025.12.004_b0170","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1158\/1078-0432.CCR-20-2063","article-title":"Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma","volume":"27","author":"Tannir","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euros.2025.12.004_b0175","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.euros.2024.09.002","article-title":"PrimerX: a Bayesian multistage cohort embedded randomised trial to evaluate the role of deferred local therapy of the primary tumour in combination with immune checkpoint inhibitor\u2013based first-line therapy in metastatic renal cell carcinoma patients","volume":"70","author":"Figaroa","year":"2024","journal-title":"Eur Urol Open Sci"}],"updated-by":[{"DOI":"10.1016\/j.euros.2026.05.009","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000}}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168325024838?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168325024838?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T21:08:53Z","timestamp":1770152933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168325024838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":35,"alternative-id":["S2666168325024838"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2025.12.004","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term Real-world Survival Outcomes with Dual Immune Checkpoint Blockade in Synchronous Metastatic Renal Cell Carcinoma: Implications for the Design of Prospective Cytoreductive Nephrectomy Trials","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2025.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}